Le Lézard
Classified in: Health, Science and technology
Subject: Conference

BioSkryb Genomics to Highlight Power of Next Generation Single-Cell Technology at AGBT 2024


BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete DNA-informed multiomic view of the cellular ecosystem, today announced that it will introduce innovative new products and present novel research at the AGBT 2024 General Meeting on February 5-8, 2024 in Orlando, Florida. As a Bronze Sponsor, BioSkryb will also host a workshop and networking event at the meeting.

"Our industry-first next generation single-cell technology offers the most comprehensive view of the integrated genome, transcriptome, and targeted proteins from each cell in a single workflow, and we are thrilled to highlight novel applications of our platforms at AGBT," said Suresh Pisharody, CEO, BioSkryb. "BioSkryb scientists will present alongside academic collaborators on a range of research areas, from enhanced understanding of early-stage breast cancer to the analysis of clonal heterogeneity in leukemia. We are excited to share this research, and we believe our distinct technology will power the next wave of large-scale single cell studies in the research and translational space."

BioSkryb will announce new single-cell core kit configurations for both the ResolveDNA® (single-cell whole genome kit) and ResolveOMEtm (single-cell whole genome and transcriptome kit) products, that will provide a streamlined and automatable workflow capable of generating sequencing-ready, DNA-informed multiomic libraries from single cells in under 8 hours. BioSkryb will also announce the upcoming ResolveXOMEtm and targeted panel single-cell enrichment modules for use with the new ResolveDNA and ResolveOME core kit configurations. These two core kits from BioSkryb allow researchers to interrogate copy number variation (CNV), structural variation (SV), single nucleotide variations (SNV), full-length transcript isoforms, on- or off- target screening in gene edited cells, cell identification, cell ploidy, fusion genes, and other true multiomic applications.

"By providing automation-friendly and instrument-free workflows, together with exome and panel-enrichment capabilities, we are now enabling our customers to cost effectively scale their single-cell research at the multiomic resolution that best fits their scientific needs. We look forward to engaging with the research community on these exciting new products at AGBT," said Aaron Llanso, Vice President of Product Management, BioSkryb.

These new product offerings will further enhance BioSkryb's portfolio, including ResolveServicesSM, which empowers custom multiomics projects across a wide range of customer applications.

BioSkryb's events at AGBT 2024 are as follows:

Workshops/Events

Posters and Presentations Featuring BioSkryb Technology

From detecting single nucleotide variants in circulating DNA to long-read sequencing, BioSkryb's poster presentations at this year's AGBT meeting will offer a look at new applications of ResolveDNA and ResolveOME technologies:

To schedule a demo or meeting at the conference, please visit the BioSkryb website.

About BioSkryb Genomics

BioSkryb Genomics is a rapidly growing organization that is transforming single cell molecular discovery and analysis. Through its single cell whole genome and whole transcriptome amplification tools, scientists and clinicians can gain an unprecedented view of the genome, transcriptome, and proteome from each single cell to better understand the drivers, mechanisms, and management of complex disease. The company is headquartered in Durham, North Carolina. For more information, visit bioskryb.com.


These press releases may also interest you

at 07:35
Thryv Holdings, Inc. ("Thryv" or the "Company"), the provider of Thryv®, the leading small business software platform, reported SaaS revenue growth of 24% year-over-year in the first quarter of 2024. "We are pleased with our first quarter results...

at 07:35
Organon today announced its results for the first quarter ended March 31, 2024. "We entered this year with a clear focus: to deliver our 2024 financial targets while staying true to our mission of improving the health of women, and the first...

at 07:35
Lantern Pharma Inc. , an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced...

at 07:32
The Shyft Group, Inc. , the North American leader in specialty vehicle manufacturing, assembly, and upfit for the commercial, retail, and specialty vehicle markets today announced a purchase order with FedEx for an initial order of 150 Blue Arctm EV...

at 07:30
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced today that the Toronto Stock Exchange ("TSX") has accepted the Company's notice of intention to implement a...

at 07:30
VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce that it will release its financial results for its first quarter 2024 ended March 30th, 2024, after market close on May 9th, 2024. The Company will subsequently hold a conference...



News published on and distributed by: